SCHEMBL6714926

SCHEMBL6714926

COc1ccc2c(c1)nc(-c1cc[nH]n1)n2-c1ccc(CCNC(=O)N(OS(=O)(=O)c2ccc(C)cc2)S(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
MAPT P10636 5/20 0.40
LMNA P02545 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PTGER1 P34995 1/20 0.38
POLB P06746 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PTGER4 P35408 1/20 0.36
RORC P51449 1/20 0.36
HPGD P15428 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA9 Q16790 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626286 0.84 PTGER4 (0.52) ALDH1A1MAPTKDM4EPTGER4CA12
SCHEMBL1625699 0.82 TP53 (0.39) ALDH1A1MAPTLMNANPSR1RORC
SCHEMBL6714921 0.82 PTGER4 (0.49) ALDH1A1MAPTKDM4EPTGER4CA12
SCHEMBL1626134 0.80 TP53 (0.37) ALDH1A1MAPTLMNANPSR1RORC
P-Toluenesulfonamide SCHEMBL1625574 0.79 CA2 (0.51) ALDH1A1MAPTPOLBKDM4EPTGER4
SCHEMBL1626194 0.77 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2POLBKDM4EHPGD
SCHEMBL5998333 0.76 PTGER4 (0.44) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL1625895 0.75 PTGER4 (0.44) ALDH1A1MAPTLMNASMN1; SMN2POLB
SCHEMBL1624941 0.73 TDP1 (0.39) ALDH1A1SMN1; SMN2POLBKDM4ETP53
SCHEMBL1625307 0.73 TAAR1 (0.41) ALDH1A1SMN1; SMN2POLBKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2004-09-16 US disclosed
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 ALDH1A1 1858/4885MAPT 4402/4885LMNA 3215/4885
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 ALDH1A1 632/4885MAPT 3288/4885LMNA 2960/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 ALDH1A1 1286/4885MAPT 4854/4885LMNA 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.